Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571541 | 0.90 | HDAC1 (0.37) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL29571625 | 0.88 | CYP2D6 (0.36) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL22118692 | 0.88 | CYP2D6 (0.36) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL29571151 | 0.88 | CYP2D6 (0.36) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL31367121 | 0.76 | SMN1; SMN2 (0.40) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL21358248 | 0.75 | SMN1; SMN2 (0.37) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL21360074 | 0.72 | SMN1; SMN2 (0.38) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL21360073 | 0.72 | SMN1; SMN2 (0.38) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL31367117 | 0.72 | NPC1 (0.36) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL21360028 | 0.71 | PDK1 (0.37) | MEN1KMT2ANPSR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4087583-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4087583-A1 | ARGINASE INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | MEN1 2856/4885KMT2A 2770/4885NPSR1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.